Financials Shenzhen Lifotronic Technology Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
20.65 ^CNY	-0.10%		+4.35%	-8.26%

22/02	Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,866	9,711	7,528	9,599	8,841	-	-
Enterprise Value (EV) ¹	8,866	9,711	7,528	9,599	8,841	8,841	8,841
P/E ratio	61.8 x	51.1 x	29.7 x	29.2 x	20.9 x	15.9 x	13.6 x
Yield	-	-	-	1.25%	1.6%	1.67%	2.32%
Capitalization / Revenue	16 x	12.5 x	7.66 x	8.38 x	6.14 x	4.71 x	4.12 x
EV / Revenue	16 x	12.5 x	7.66 x	8.38 x	6.14 x	4.71 x	4.12 x
EV / EBITDA	-	43.8 x	26.9 x	25.7 x	19.7 x	14.1 x	12.6 x
EV / FCF	-	-	-	37.5 x	26.5 x	19.3 x	16.5 x
FCF Yield	-	-	-	2.67%	3.78%	5.18%	6.06%
Price to Book	-	7.73 x	5.23 x	5.36 x	4.26 x	3.58 x	3.09 x
Nbr of stocks (in thousands)	4,22,200	4,22,200	4,22,200	4,26,417	4,28,114	-	-
Reference price ²	21.00	23.00	17.83	22.51	20.65	20.65	20.65
Announcement Date	19/03/21	25/02/22	10/02/23	22/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	553.8	778.1	983	1,146	1,440	1,877	2,146
EBITDA ¹	-	221.6	280.3	372.8	448.4	628	701.4
EBIT ¹	-	203.1	256.4	345	448.8	594.8	695.9
Operating Margin	-	26.1%	26.08%	30.12%	31.18%	31.69%	32.44%
Earnings before Tax (EBT) ¹	-	202.8	256.5	344.5	448.4	594.7	695.8
Net income ¹	143.9	190	251.5	328.6	423.4	556.8	649.9
Net margin	25.99%	24.42%	25.58%	28.68%	29.41%	29.66%	30.29%
EPS ²	0.3400	0.4500	0.6000	0.7700	0.9867	1.302	1.517
Free Cash Flow ¹	-	-	-	255.9	334	458	536
FCF margin	-	-	-	22.33%	23.2%	24.4%	24.98%
FCF Conversion (EBITDA)	-	-	-	68.64%	74.49%	72.93%	76.42%
FCF Conversion (Net income)	-	-	-	77.87%	78.88%	82.26%	82.47%
Dividend per Share ²	-	-	-	0.2810	0.3300	0.3450	0.4800
Announcement Date	19/03/21	25/02/22	10/02/23	22/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	256	334	458	536
ROE (net income / shareholders' equity)	-	16.1%	18.8%	20.4%	20.4%	22.6%	22.7%
ROA (Net income/ Total Assets)	-	-	-	14%	15.4%	18.6%	17.2%
Assets ¹	-	-	-	2,342	2,750	2,994	3,779
Book Value Per Share ²	-	2.970	3.410	4.200	4.850	5.770	6.690
Cash Flow per Share ²	-	0.4300	0.6400	0.7100	0.7800	1.820	0.7600
Capex ¹	-	-	184	47.9	89.5	121	94
Capex / Sales	-	-	18.67%	4.18%	6.22%	6.43%	4.38%
Announcement Date	19/03/21	25/02/22	10/02/23	22/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.65 CNY

Average target price

23.86 CNY

Spread / Average Target

+15.57%

	1st Jan change	Capi.
SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD.	-8.26%	1.22B
BIOMÉRIEUX	-4.67%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.19%	8.07B
DIASORIN S.P.A.	+9.45%	5.91B
LANTHEUS HOLDINGS, INC.	+28.50%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-8.09%	4.21B
10X GENOMICS, INC.	-55.31%	2.99B
ANDON HEALTH CO., LTD.	+13.49%	2.73B
VITROLIFE AB	-1.34%	2.43B
MYRIAD GENETICS, INC.	+32.24%	2.29B